Multimodal Integration of Gait Dysfunction, Amyloid PET , and Plasma Biomarkers for Differentiating Etiological Subtypes in Mild Cognitive Impairment
CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)
DOI: 10.1002/cns.70949 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 05.06.2026. Verfasst von Jiaonan Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Positron-Emission Tomography, Amyloid beta-Peptides, Gait Disorders, Neurologic. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Strategic Priority Research Program of the Chinese Academy of Sciences, Anhui Provincial Key R&D Programs, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Objective
To investigate gait characteristics and plasma biomarkers in individuals with mild cognitive impairment (MCI) stratified by amyloid‐β (Aβ) positivity on positron emission tomography (PET), and to evaluate the predictive value for Alzheimer's disease (AD)–related MCI.
Methods
A total of 168 participants were enrolled, including 50 amyloid PET‐negative MCI (MCI‐), 51 amyloid PET‐positive MCI (MCI+), and 61 cognitively normal (CN) individuals. Gait assessments were conducted using a multi‐sensor motion analysis system during dual‐task paradigms (cognitive load superimposed on locomotion). Plasma samples were analyzed for neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau at threonine 217 (p‐tau217) via ultra‐sensitive immunoassays.
Results
Gait analyses identified 125 features, with 69 distinguishing MCI+ from CN and 36 differentiating MCI+ from MCI‐. Receiver operating characteristic (ROC) analyses showed that dual‐task gait under the countdown and animal‐naming conditions (gait‐countdown [GCD] and gait‐animal naming [GAN]) discriminated MCI+ from CN with an AUC of 0.850. The combined models integrating GCD and GAN with plasma GFAP or p‐tau217 yielded AUCs of 0.919 and 0.951, respectively. Similarly, GCD&GAN features demonstrated an AUC of 0.862 for distinguishing MCI+ from MCI−, with GFAP (AUC = 0.933) and p‐tau217 (AUC = 0.986) enhancing predictive performance.
Conclusion
This study provides evidence that dual‐task gait assessments, when combined with plasma biomarkers such as GFAP and p‐tau217, may improve the discriminatory power for identifying AD‐related MCI. The integration of biomechanical and molecular markers holds promise for advancing early detection strategies and therapeutic monitoring in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Graduate School, Bengbu Medical University, Bengbu, China.
- Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
ORCID-Profile: Jiong Shi
Förderung
- the Strategic Priority Research Program of the Chinese Academy of Sciences
- Anhui Provincial Key R&D Programs
- Fundamental Research Funds for the Central Universities
- Natural Science Research Projects in Anhui Province Universities
- Anhui Provincial Clinical Medical Research and Translation Special Fund
- Natural Science Foundation of Anhui Province
Zitieren
APA
Wu, J., Tang, F., Lv, X., Wang, Y., Gao, F., Shen, Y., Cheng, Z., & Shi, J. (2026). Multimodal Integration of Gait Dysfunction, Amyloid PET , and Plasma Biomarkers for Differentiating Etiological Subtypes in Mild Cognitive Impairment. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70949
Vancouver
Wu J, Tang F, Lv X, Wang Y, Gao F, Shen Y, et al. Multimodal Integration of Gait Dysfunction, Amyloid PET , and Plasma Biomarkers for Differentiating Etiological Subtypes in Mild Cognitive Impairment. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70949
BibTeX
@article{Wu2026,
author = {Wu, Jiaonan and Tang, Fang and Lv, Xinyi and Wang, Yiwei and Gao, Feng and Shen, Yong and Cheng, Zhaozhao and Shi, Jiong},
title = {Multimodal Integration of Gait Dysfunction, Amyloid PET , and Plasma Biomarkers for Differentiating Etiological Subtypes in Mild Cognitive Impairment},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {6},
doi = {10.1002/cns.70949}
}
EUVIMED